Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 5
2016 1
2017 3
2018 2
2019 5
2020 2
2021 7
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. von Herrath M, et al. Among authors: morales c. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. Lancet Diabetes Endocrinol. 2021. PMID: 33662334 Clinical Trial.
Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.
Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, Brito-Sanfiel M, Umpierrez G. Gomez-Peralta F, et al. Among authors: morales c. Diabetes Ther. 2017 Oct;8(5):953-962. doi: 10.1007/s13300-017-0277-0. Epub 2017 Jul 18. Diabetes Ther. 2017. PMID: 28721687 Free PMC article. Review.
Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
Heerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, Maklad N, Perl S, Eklund O, Rikte T, Sjöström CD, Perkovic V; SAPPHIRE Investigators. Heerspink HJL, et al. J Am Soc Nephrol. 2024 May 1;35(5):594-606. doi: 10.1681/ASN.0000000000000326. Epub 2024 Feb 20. J Am Soc Nephrol. 2024. PMID: 38564654 Clinical Trial. No abstract available.
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
García de Lucas MD, Caballero I, Fernández-García JC, Domínguez-Rodríguez M, Moreno-Moreno P, Jiménez-Millán A, Botana-López M, Avilés B, Merino-Torres JF, Soto A, Tejera C, Morales C. García de Lucas MD, et al. Among authors: morales c. Front Endocrinol (Lausanne). 2023 Oct 24;14:1240279. doi: 10.3389/fendo.2023.1240279. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37955013 Free PMC article.
Visual field progression in patients with severe glaucoma.
Maul EJ, Kastner A, Schmidt J, Tapia JA, Morales C, Maul EA. Maul EJ, et al. Among authors: morales c. Graefes Arch Clin Exp Ophthalmol. 2021 Jun;259(6):1579-1586. doi: 10.1007/s00417-020-05036-5. Epub 2021 Jan 8. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33417091
31 results